REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Virus + drug combo tested for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC